Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β-cells

Journal of Clinical Biochemistry and Nutrition

Volumn 48, Issue 3, 2011, Pages 237-244

  Minakawa, Miki ^a   Kawano, Atutoshi ^a   Miura, Yutaka ^a   Yagasaki, Kazumi ^a,b  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

AMPK signaling; Myotube; Pancreatic cell; Resveratrol; Type 2 diabetic db db mouse

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIPID PEROXIDE; RESVERATROL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL PROTECTION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; MALE; MOUSE; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; RAT; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

MUS; VITACEAE;

EID: 79955441995     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.10-119     Document Type: Article

References (60)

1. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-827. (Pubitemid 34000786)
2. Banskota AH, Nguyen NT, Tezuka Y, Nobukawa T, Kadota S. Hypoglycemic effects of the wood of Taxus yunnanensis on streptozotocin-induced diabetic rats and its active components. Phytomedicine 2006; 13: 109-114. (Pubitemid 41797598)
3. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130-1134. (Pubitemid 29230961)
4. Genuth S, Alberti KG, Bennett P, and et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444. (Pubitemid 23046633)
6. Verdecchia P, Reboldi G, Angeli F, and et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969. (Pubitemid 38579899)
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145-153.
8. Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010; 453892. DOI: 10.115/2010/453892.
9. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806. (Pubitemid 34000783)
10. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-341.
11. Hardie DG. AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med Sci Sports Exerc 2004; 36: 28-34. (Pubitemid 38090550)
12. Zou MH, Kirkpatrick SS, Davis BJ, and et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004; 279: 43940-43951. (Pubitemid 39390702)
13. Konrad D, Rudich A, Bilan PJ, and et al. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 2005; 48: 954-966. (Pubitemid 40767990)
14. Brownlee MA, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
15. Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med 1999; 5: 393-405. (Pubitemid 29382313)
16. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007; 27: 130-143.
17. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E694.
18. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955. (Pubitemid 32946067)
19. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272: 16498-16506. (Pubitemid 27276477)
20. Hudson BI, Wendt T, Bucciarelli LG, and et al. Diabetic vascular disease: It's all the rage. Antioxid Redox Signal 2005; 7: 1588-1600. (Pubitemid 41767994)
21. Soro-Paavonen A, Watson AM, Li J, and et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-2469.
22. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605. (Pubitemid 44199649)
23. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 1996; 20: 463-466. (Pubitemid 26077870)
24. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-1742. (Pubitemid 27456404)
25. Bhardwaj A, Sethi G, Vadhan-Raj S, and et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through downregulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-2302. (Pubitemid 46425866)
26. Das S, Fraga CG, Das DK. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFκB. Free Radic Res 2006; 40: 1066-1075. (Pubitemid 44480547)
27. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001; 61: 7456-7463. (Pubitemid 32995034)
28. Lee M, Kim S, Kwon OK, Oh SR, Lee HK, Ahn K. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol 2009; 9: 418-424.
29. Jia Z, Zhu H, Misra BR, Mahaney JE, Li Y, Misra HP. EPR studies on the superoxide-scavenging capacity of the nutraceutical resveratrol. Mol Cell Biochem 2008; 313: 187-194.
30. Lin KH, Hsiao G, Shih CM, Chou DS, Sheu JR. Mechanisms of resveratrolinduced platelet apoptosis. Cardiovasc Res 2009; 83: 575-585.
31. Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002; 9: 77-79.
32. Baur JA, Pearson KJ, Price NL, and et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342.
33. Ates O, Cayli S, Altinoz E, and et al. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 2007; 294: 137-144. (Pubitemid 46188894)
34. Kozuki Y, Miura Y, Yagasaki K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett 2001; 167: 151-156. (Pubitemid 32706677)
35. Miura D, Miura Y, Yagasaki K. Restoration by prostaglandins E2 and F2α of resveratrol-induced suppression of hepatoma cell invasion in culture. Cytotechnology 2003; 43: 155-159. (Pubitemid 41184378)
36. Miura D, Miura Y, Yagasaki K. Resveratrol inhibits hepatoma cell invasion by suppressing gene expression of hepatocyte growth factor via its reactive oxygen species-scavenging property. Clin Exp Metastasis 2004; 21: 445-451.
37. Nihei T, Miura Y, Yagasaki K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life Sci 2001; 68: 2845-2852. (Pubitemid 32448890)
38. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 2003; 73: 1393-1400. (Pubitemid 36798126)
39. Coleman DL. Diabetes-obesity syndromes in mice. Diabetes 1982; 31: 1-6. (Pubitemid 12128678)
40. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144. (Pubitemid 36578440)
41. Yaffe D. Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proc Natl Acad Sci USA 1968; 61: 477-483.
42. Chick WL, Warren S, Chute RN, Like AA, Lauris V, Kitchen KC. A transplantable insulinoma in the rat. Proc Natl Acad Sci USA 1977; 74: 628-632. (Pubitemid 8038777)
43. Kawano A, Nakamura H, Hata S, Minakawa M, Miura Y, Yagasaki K. Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009; 16: 437-443.
44. Kume S, Kato S, Yamagishi S, and et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20: 1647-1658. (Pubitemid 41243553)
45. Yagasaki K, Morisaki N, Kitahara Y, Miura A, Funabiki R. Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in L6 myotubes. Cytotechnology 2003; 43: 97-103. (Pubitemid 41184370)
46. 12 myotubes. Biochem Biophys Res Commun 2003; 312: 1111-1117.
47. Nishiumi S, Ashida H. Rapid preparation of a plasma membrane fraction from adipocytes and muscle cells: application to detection of translocated glucose transporter 4 on the plasma membrane. Biosci Biotechnol Biochem 2007; 71: 2343-2346. (Pubitemid 350113120)
48. Mendis E, Kim MM, Rajapakse N, Kim SK. An in vitro cellular analysis of the radical scavenging efficacy of chitooligosaccharides. Life Sci 2007; 80: 2118-2127. (Pubitemid 46755330)
49. Walton M, Sirimanne E, Reutelingsperger C, Williams C, Gluckman P, Dragunow M. Annexin V labels apoptotic neurons following hypoxia-ischemia. Neuroreport 1997; 18: 3871-3875. (Pubitemid 28027201)
50. Herman HA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 2006; 116: 1767-1775. (Pubitemid 44033296)
51. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise: how is it regulated? Physiology 2005; 20: 260-270.
52. Miura Y, Ono K, Okauchi R, Yagasaki K. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatoma-bearing rats. J Nutr Sci Vitaminol 2004; 50: 38-44. (Pubitemid 38405207)
53. Modak M, Dixut P, Londhe J, Ghaskadbi S, Devasagyam TPA. Indian herbes and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 2007; 40: 163-173. (Pubitemid 46984209)
54. Afolayan AJ, Sunmonu TO. In vivo studies on antidiabetic plants used in South African herbal medicine. J Clin Biochem Nutr 2010; 47: 98-106.
55. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006; 290: E1339-E1346.
56. Breen DM, Sanli T, Giacca A, Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 2008; 374: 117-122.
57. Deng JY, Hsieh PS, Huang JP, Lu LS, Hung LM. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 2008; 57: 1814-1823.
58. Lastra G, Whaley-Connell A, Manrique C, and et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008; 295: E110-E116.
59. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck LR. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009; 119: 1643-1652.
60. Jing YH, Chen KH, Yang SH, Kuo PC, Chen JK. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 2010; 26: 212-222.